The role of Epstein-Barr virus in autoimmune and autoinflammatory diseases

References

• Afrasiabi A, Parnell GP, Fewings N, Schibeci SD, Basuki MA, Chandramohan R, Zhou Y, Taylor B, Brown DA, Swaminathan S, et al. 2019. Evidence from genome wide association studies implicates reduced control of Epstein-Barr virus infection in multiple sclerosis susceptibility. Genome Med. 11(1):26. doi:10.1186/s13073-019-0640-z.
   PubMedGoogle Scholar
• Afrasiabi A, Parnell GP, Swaminathan S, Stewart GJ, Booth DR. 2020. The interaction of multiple sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis. Sci Rep. 10(1):193. doi:10.1038/s41598-019-55850-z.
   PubMed Web of Science ®Google Scholar
• Afzal M, Nigam GB. 2018. EBV colitis with ulcerative colitis: a double whammy. BMJ Case Rep. 2018 doi:10.1136/bcr-2018-224963.
   PubMedGoogle Scholar
• Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. 2004. Epstein-Barr virus in pediatric multiple sclerosis. JAMA. 291(15):1875–1879. doi:10.1001/jama.291.15.1875.
   PubMed Web of Science ®Google Scholar
• Alspaugh MA, Henle G, Lennette ET, Henle W. 1981. Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis. J Clin Invest. 67(4):1134–1140. doi:10.1172/jci110127.
   PubMed Web of Science ®Google Scholar
• Andari S, Hussein H, Fadlallah S, Jurjus AR, Shirinian M, Hashash JG, Rahal EA. 2021. Epstein-Barr Virus DNA Exacerbates Colitis Symptoms in a Mouse Model of Inflammatory Bowel Disease. Viruses. 13(7):1272. doi:10.3390/v13071272.
   PubMed Web of Science ®Google Scholar
• Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, et al. 2013. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 9(4):e1003220. doi:10.1371/journal.ppat.1003220.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernán MA, Olek MJ, Hankinson SE, Hunter DJ. 2001. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA. 286(24):3083–3088. doi:10.1001/jama.286.24.3083.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL, Lünemann JD. 2012. The initiation and prevention of multiple sclerosis. Nat Rev Neurol. 8(11):602–612. doi:10.1038/nrneurol.2012.198.
   PubMed Web of Science ®Google Scholar
• Aygun D, Kuskucu MA, Sahin S, Adrovic A, Barut K, Yıldız M, Sharifova S, Midilli K, Cokugras H, Camcıoglu Y, et al. 2020. Epstein-Barr virus, cytomegalovirus and BK polyomavirus burden in juvenile systemic lupus erythematosus: correlation with clinical and laboratory indices of disease activity. Lupus. 29(10):1263–1269. doi:10.1177/0961203320940029.
   PubMed Web of Science ®Google Scholar
• Bachmann J, Le Thi G, Bruckner A, Kalteis AL, Schwerd T, Koletzko S, Eberhard L. 2021. Epstein-Barr virus prevalence at diagnosis and seroconversion during follow-up in pediatric inflammatory bowel disease. J Clin Med. 10(21):5187.
   Web of Science ®Google Scholar
• Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundström C, et al. 2006. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54(3):692–701. doi:10.1002/art.21675.
   PubMed Web of Science ®Google Scholar
• Balandraud N, Meynard JB, Auger I, Sovran H, Mugnier B, Reviron D, Roudier J, Roudier C. 2003. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum. 48(5):1223–1228. doi:10.1002/art.10933.
   PubMed Web of Science ®Google Scholar
• Balandraud N, Roudier J. 2018. Epstein-Barr virus and rheumatoid arthritis. Joint Bone Spine. 85(2):165–170. doi:10.1016/j.jbspin.2017.04.011.
   PubMed Web of Science ®Google Scholar
• Banko A, Miljanovic D, Lazarevic I, Jeremic I, Despotovic A, Grk M, Cirkovic A. 2022. New evidence of significant association between EBV presence and lymphoproliferative disorders susceptibility in patients with rheumatoid arthritis: a systematic review with meta-analysis. Viruses. 14(1):115. doi:10.3390/v14010115.
   PubMed Web of Science ®Google Scholar
• Barcelos F, Martins C, Monteiro R, Cardigos J, Prussiani T, Sítima M, Alves N, Vaz-Patto J, Cunha-Branco J, Borrego L-M, et al. 2021. Association between EBV serological patterns and lymphocytic profile of SjS patients support a virally triggered autoimmune epithelitis. Sci Rep. 11(1):4082. doi:10.1038/s41598-021-83550-0.
   PubMed Web of Science ®Google Scholar
• Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, Fan B, O’Connor RA, Anderton SM, Bar-Or A, et al. 2012. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. 209(5):1001–1010. doi:10.1084/jem.20111675.
   PubMed Web of Science ®Google Scholar
• Berner BR, Tary-Lehmann M, Yonkers NL, Askari AD, Lehmann PV, Anthony DD. 2005. Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. Cell Immunol. 235(1):29–38. doi:10.1016/j.cellimm.2005.06.010.
   PubMed Web of Science ®Google Scholar
• Bian X, Wallstrom G, Davis A, Wang J, Park J, Throop A, Steel J, Yu X, Wasserfall C, Schatz D, et al. 2016. Immunoproteomic profiling of antiviral antibodies in new-onset type 1 diabetes using protein arrays. Diabetes. 65(1):285–296. doi:10.2337/db15-0179.
   PubMed Web of Science ®Google Scholar
• Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, Elledge SJ, Niebuhr DW, Scher AI, Munger KL, et al. 2022. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 375(6578):296–301. doi:10.1126/science.abj8222.
   PubMed Web of Science ®Google Scholar
• Blaschke S, Schwarz G, Moneke D, Binder L, Müller G, Reuss-Borst M. 2000. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis. J Rheumatol. 27(4):866–873.
   PubMed Web of Science ®Google Scholar
• Bo M, Niegowska M, Erre GL, Piras M, Longu MG, Manchia P, Manca M, Passiu G, Sechi LA. 2018. Rheumatoid arthritis patient antibodies highly recognize IL-2 in the immune response pathway involving IRF5 and EBV antigens. Sci Rep. 8(1):1789. doi:10.1038/s41598-018-19957-z.
   PubMedGoogle Scholar
• Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, Sivils K, Theander E, Tzioufas A, Ramos-Casals M, et al. 2016. Sjögren syndrome. Nat Rev Dis Primers. 2(1):16047. doi:10.1038/nrdp.2016.47.
   PubMedGoogle Scholar
• Buonavoglia A, Leone P, Prete M, Solimando AG, Guastadisegno C, Lanave G, Camero M, Martella V, Lo Muzio L, and Racanelli V. 2021. Epstein-Barr virus in salivary samples from systemic lupus erythematosus patients with oral lesions. J Clin Med. 10(21):4995.
   PubMed Web of Science ®Google Scholar
• Burnard S, Lechner-Scott J, Scott RJ. 2017. EBV and MS: major cause, minor contribution or red-herring? Mult Scler Relat Disord. 16:24–30. doi:10.1016/j.msard.2017.06.002.
   PubMed Web of Science ®Google Scholar
• Calabretto M, Di Carlo D, Falasca F, Mazzuti L, Meacci A, Donato G, Greco N, Mezzatesta L, Morrone A, Turriziani O, et al. 2022. Analysis of viral nucleic acids in duodenal biopsies from adult patients with celiac disease. Eur J Gastroenterol Hepatol. 34(11):1107–1110. doi:10.1097/MEG.0000000000002404.
   PubMed Web of Science ®Google Scholar
• Cassaniti I, Cavagna L, Calarota SA, Adzasehoun KMG, Comolli G, Montecucco C, Baldanti F. 2019. Evaluation of EBV- and HCMV-specific T cell responses in systemic lupus erythematosus (SLE) patients using a normalized enzyme-linked immunospot (ELISPOT) assay. J Immunol Res. 2019:4236503–4236512. doi:10.1155/2019/4236503.
   PubMed Web of Science ®Google Scholar
• Catassi C, Verdu EF, Bai JC, Lionetti E. 2022. Coeliac disease. Lancet. 399(10344):2413–2426. doi:10.1016/S0140-6736(22)00794-2.
   PubMed Web of Science ®Google Scholar
• Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, Sommer N, Hartung H-P, Hemmer B. 2005. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain. 128(Pt 7):1667–1676. doi:10.1093/brain/awh486.
   PubMed Web of Science ®Google Scholar
• Chen T, Hudnall SD. 2006. Anatomical mapping of human herpesvirus reservoirs of infection. Mod Pathol. 19(5):726–737. doi:10.1038/modpathol.3800584.
   PubMed Web of Science ®Google Scholar
• Choi C, Yu Q, Deb PQ, Wang W. 2020. Rare case of EBV-induced colitis in an immunocompetent individual. BMJ Open Gastroenterol. 7(1):e000360. doi:10.1136/bmjgast-2019-000360.
   PubMed Web of Science ®Google Scholar
• Christen U. 2019. Pathogen infection and autoimmune disease. Clin Exp Immunol. 195(1):10–14. doi:10.1111/cei.13239.
   PubMed Web of Science ®Google Scholar
• Ciccocioppo R, Racca F, Paolucci S, Campanini G, Pozzi L, Betti E, Riboni R, Vanoli A, Baldanti F, Corazza GR, et al. 2015. Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement. World J Gastroenterol. 21(6):1915–1926. doi:10.3748/wjg.v21.i6.1915.
   PubMed Web of Science ®Google Scholar
• Ciccocioppo R, Racca F, Scudeller L, Piralla A, Formagnana P, Pozzi L, Betti E, Vanoli A, Riboni R, Kruzliak P, et al. 2016. Differential cellular localization of Epstein-Barr virus and human cytomegalovirus in the colonic mucosa of patients with active or quiescent inflammatory bowel disease. Immunol Res. 64(1):191–203. doi:10.1007/s12026-015-8737-y.
   PubMed Web of Science ®Google Scholar
• Corcione A, Casazza S, Ferretti E, Giunti D, Zappia E, Pistorio A, Gambini C, Mancardi GL, Uccelli A, Pistoia V, et al. 2004. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A. 101(30):11064–11069. doi:10.1073/pnas.0402455101.
   PubMed Web of Science ®Google Scholar
• Croia C, Astorri E, Murray-Brown W, Willis A, Brokstad KA, Sutcliffe N, Piper K, Jonsson R, Tappuni AR, Pitzalis C, et al. 2014. Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjögren’s syndrome. Arthritis Rheumatol. 66(9):2545–2557. doi:10.1002/art.38726.
   PubMed Web of Science ®Google Scholar
• Croia C, Serafini B, Bombardieri M, Kelly S, Humby F, Severa M, Rizzo F, Coccia EM, Migliorini P, Aloisi F, et al. 2013. Epstein-Barr virus persistence and infection of autoreactive plasma cells in synovial lymphoid structures in rheumatoid arthritis. Ann Rheum Dis. 72(9):1559–1568. doi:10.1136/annrheumdis-2012-202352.
   PubMed Web of Science ®Google Scholar
• de Francisco R, Castaño-García A, Martínez-González S, Pérez-Martínez I, González-Huerta AJ, Morais LR, Fernández-García MS, Jiménez S, Díaz-Coto S, Flórez-Díez P, et al. 2018. Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease. Aliment Pharmacol Ther. 48(7):723–730. doi:10.1111/apt.14933.
   PubMed Web of Science ®Google Scholar
• Decker P, Moulinet T, Pontille F, Cravat M, De Carvalho Bittencourt M, Jaussaud R. 2022. An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management. Autoimmun Rev. 21(3):103013. doi:10.1016/j.autrev.2021.103013.
   PubMed Web of Science ®Google Scholar
• Dimitroulia E, Pitiriga VC, Piperaki ET, Spanakis NE, Tsakris A. 2013. Inflammatory bowel disease exacerbation associated with Epstein-Barr virus infection. Dis Colon Rectum. 56(3):322–327. doi:10.1097/DCR.0b013e31827cd02c.
   PubMed Web of Science ®Google Scholar
• Doaty S, Agrawal H, Bauer E, Furst DE. 2016. Infection and Lupus: which Causes Which? Curr Rheumatol Rep. 18(3):13. doi:10.1007/s11926-016-0561-4.
   PubMed Web of Science ®Google Scholar
• Dooley MM, de Gannes SL, Fu KA, Lindsey JW. 2016. The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins. J Neuroimmunol. 299:147–151. doi:10.1016/j.jneuroim.2016.08.016.
   PubMed Web of Science ®Google Scholar
• Doshi A, Chataway J. 2016. Multiple sclerosis, a treatable disease. Clin Med (Lond). 16(Suppl 6):s53–s59. doi:10.7861/clinmedicine.16-6-s53.
   PubMedGoogle Scholar
• Draborg AH, Duus K, Houen G. 2012. Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol. 2012:370516–370510. doi:10.1155/2012/370516.
   PubMedGoogle Scholar
• Draborg AH, Duus K, Houen G. 2013. Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol. 2013:535738–535739. doi:10.1155/2013/535738.
   PubMedGoogle Scholar
• Dreyfus DH, Liu Y, Ghoda LY, Chang JT. 2011. Analysis of an ankyrin-like region in Epstein Barr Virus encoded (EBV) BZLF-1 (ZEBRA) protein: implications for interactions with NF-κB and p53. Virol J. 8(1):422. doi:10.1186/1743-422X-8-422.
   PubMedGoogle Scholar
• Dreyfus DH, Nagasawa M, Gelfand EW, Ghoda LY. 2005. Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors. BMC Immunol. 6(1):12. doi:10.1186/1471-2172-6-12.
   PubMedGoogle Scholar
• Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim HJ, Bar-Or A. 2007. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol. 178(10):6092–6099. doi:10.4049/jimmunol.178.10.6092.
   PubMed Web of Science ®Google Scholar
• Dunmire SK, Verghese PS, Balfour HH.Jr. 2018. Primary Epstein-Barr virus infection. J Clin Virol. 102:84–92. doi:10.1016/j.jcv.2018.03.001.
   PubMed Web of Science ®Google Scholar
• Emadi B, Carter M, Eswar S, Chen X, Laurynenka V, Parameswaran S, Kaufman KM, Namjou B, Kottyan LC, Weirauch M, et al. 2020. P136 Epstein-Barr virus transcription co-factors bind to many inflammatory bowel disease risk loci. Inflammatory Bowel Diseases. 26(Supplement_1):S31–S31. doi:10.1093/ibd/zaa010.077.
   Google Scholar
• Esposito S, Bosis S, Semino M, Rigante D. 2014. Infections and systemic lupus erythematosus. Eur J Clin Microbiol Infect Dis. 33(9):1467–1475. doi:10.1007/s10096-014-2098-7.
   PubMed Web of Science ®Google Scholar
• Fadlallah S, Hussein H, Jallad M-A, Shehab M, Jurjus AR, Matar GM, Rahal EA. 2021. Effect of Epstein-Barr virus DNA on the incidence and severity of arthritis in a rheumatoid arthritis mouse model. Front Immunol. 12:672752. doi:10.3389/fimmu.2021.672752.
   PubMed Web of Science ®Google Scholar
• Fahey LM, Wilson EB, Elsaesser H, Fistonich CD, McGavern DB, Brooks DG. 2011. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J Exp Med. 208(5):987–999. doi:10.1084/jem.20101773.
   PubMed Web of Science ®Google Scholar
• Fåhraeus R, Rymo L, Rhim JS, Klein G. 1990. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature. 345(6274):447–449. doi:10.1038/345447a0.
   PubMed Web of Science ®Google Scholar
• Feng W-h, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, Raab-Traub N, Delecluse H-J, Kenney SC. 2004. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 96(22):1691–1702. doi:10.1093/jnci/djh313.
   PubMedGoogle Scholar
• Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. 2002. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 3(10):944–950. doi:10.1038/ni833.
   PubMed Web of Science ®Google Scholar
• Finckh A, Gilbert B, Hodkinson B, Bae S-C, Thomas R, Deane KD, Alpizar-Rodriguez D, Lauper K. 2022. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 18(10):591–602. doi:10.1038/s41584-022-00827-y.
   PubMed Web of Science ®Google Scholar
• Fugl A, Andersen CL. 2019. Epstein-Barr virus and its association with disease - a review of relevance to general practice. BMC Fam Pract. 20(1):62. doi:10.1186/s12875-019-0954-3.
   PubMedGoogle Scholar
• Gehlert T, Devergne O, Niedobitek G. 2004. Epstein-Barr virus (EBV) infection and expression of the interleukin-12 family member EBV-induced gene 3 (EBI3) in chronic inflammatory bowel disease. J Med Virol. 73(3):432–438. doi:10.1002/jmv.20109.
   PubMed Web of Science ®Google Scholar
• Getts DR, Chastain EM, Terry RL, Miller SD. 2013. Virus infection, antiviral immunity, and autoimmunity. Immunol Rev. 255(1):197–209. doi:10.1111/imr.12091.
   PubMed Web of Science ®Google Scholar
• Gillespie KM. 2006. Type 1 diabetes: pathogenesis and prevention. CMAJ. 175(2):165–170. doi:10.1503/cmaj.060244.
   PubMed Web of Science ®Google Scholar
• Gugliesi F, Pasquero S, Griffante G, Scutera S, Albano C, Pacheco SFC, Riva G, Dell’Oste V, Biolatti M. 2021. Human Cytomegalovirus and Autoimmune Diseases: where Are We? Viruses. 13(2):260. doi:10.3390/v13020260.
   PubMed Web of Science ®Google Scholar
• Haas J, Bekeredjian-Ding I, Milkova M, Balint B, Schwarz A, Korporal M, Jarius S, Fritz B, Lorenz H-M, Wildemann B, et al. 2011. B cells undergo unique compartmentalized redistribution in multiple sclerosis. J Autoimmun. 37(4):289–299. doi:10.1016/j.jaut.2011.08.003.
   PubMed Web of Science ®Google Scholar
• Hammarskjöld ML, Simurda MC. 1992. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity. J Virol. 66(11):6496–6501. doi:10.1128/JVI.66.11.6496-6501.1992.
   PubMed Web of Science ®Google Scholar
• Hanlon P, Avenell A, Aucott L, Vickers MA. 2014. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther. 16(1):R3. doi:10.1186/ar4429.
   PubMed Web of Science ®Google Scholar
• Hara S, Nagata K, Kumata K, Matsushita M, Kuwamoto S, Kato M, Hayashi K. 2018. Estradiol affects Epstein-Barr virus reactivation-induced thyrotropin receptor antibody and immunoglobulin production in Graves’ disease patients and healthy controls. Viral Immunol. 31(7):486–491. doi:10.1089/vim.2018.0032.
   PubMed Web of Science ®Google Scholar
• Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, Magnusen AF, Lynch A, Chetal K, Yukawa M, et al. 2018. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet. 50(5):699–707. doi:10.1038/s41588-018-0102-3.
   PubMed Web of Science ®Google Scholar
• Harms RZ, Ostlund KR, Cabrera MS, Edwards E, Fisher M, Sarvetnick N. 2020. Confirmation and identification of biomarkers implicating environmental triggers in the pathogenesis of type 1 diabetes. Front Immunol. 11:1922. doi:10.3389/fimmu.2020.01922.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, et al. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 358(7):676–688. doi:10.1056/NEJMoa0706383.
   PubMed Web of Science ®Google Scholar
• Hedström AK, Huang J, Brenner N, Butt J, Kockum I, Waterboer T, Olsson T, Alfredsson L. 2021. Low sun exposure acts synergistically with high Epstein-Barr nuclear antigen 1 (EBNA-1) antibody levels in multiple sclerosis etiology. Eur J Neurol. 28(12):4146–4152. doi:10.1111/ene.15082.
   PubMed Web of Science ®Google Scholar
• Hedström AK, Lima Bomfim I, Hillert J, Olsson T, Alfredsson L. 2015. Obesity interacts with infectious mononucleosis in risk of multiple sclerosis. Eur J Neurol. 22(3):578–e38. doi:10.1111/ene.12620.
   PubMed Web of Science ®Google Scholar
• Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. 1991. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 65(7):1107–1115. doi:10.1016/0092-8674(91)90007-l.
   PubMed Web of Science ®Google Scholar
• Hong T, Parameswaran S, Donmez OA, Miller D, Forney C, Lape M, Saint Just Ribeiro M, Liang J, Edsall LE, Magnusen AF, et al. 2021. Epstein-Barr virus nuclear antigen 2 extensively rewires the human chromatin landscape at autoimmune risk loci. Genome Res. 31(12):2185–2198. doi:10.1101/gr.264705.120.
   PubMed Web of Science ®Google Scholar
• Hornef MW, Wagner HJ, Kruse A, Kirchner H. 1995. Cytokine production in a whole-blood assay after Epstein-Barr virus infection in vivo. Clin Diagn Lab Immunol. 2(2):209–213. doi:10.1128/cdli.2.2.209-213.1995.
   PubMedGoogle Scholar
• Hosomi S, Nishida Y, Fujiwara Y. 2021. The impact of human herpesviruses in clinical practice of inflammatory bowel disease in the era of COVID-19. Microorganisms. 9(9):1870. doi:10.3390/microorganisms9091870.
   PubMed Web of Science ®Google Scholar
• Houen G, Trier NH. 2020. Epstein-Barr virus and systemic autoimmune diseases. Front Immunol. 11:587380. doi:10.3389/fimmu.2020.587380.
   PubMed Web of Science ®Google Scholar
• Hradsky O, Copova I, Zarubova K, Durilova M, Nevoral J, Maminak M, Hubacek P, Bronsky J. 2015. Seroprevalence of Epstein-Barr virus, cytomegalovirus, and polyomaviruses in children with inflammatory bowel disease. Dig Dis Sci. 60(11):3399–3407. doi:10.1007/s10620-015-3764-z.
   PubMed Web of Science ®Google Scholar
• Hussein HM, Rahal EA. 2019. The role of viral infections in the development of autoimmune diseases. Crit Rev Microbiol. 45(4):394–412. doi:10.1080/1040841X.2019.1614904.
   PubMed Web of Science ®Google Scholar
• Hyöty H, Räsänen L, Hiltunen M, Lehtinen M, Huupponen T, Leinikki P. 1991. Decreased antibody reactivity to Epstein-Barr virus capsid antigen in type 1 (insulin-dependent) diabetes mellitus. APMIS. 99(4):359–363. doi:10.1111/j.1699-0463.1991.tb05162.x.
   PubMed Web of Science ®Google Scholar
• Inoue H, Mishima K, Yamamoto-Yoshida S, Ushikoshi-Nakayama R, Nakagawa Y, Yamamoto K, Ryo K, Ide F, Saito I. 2012. Aryl hydrocarbon receptor-mediated induction of EBV reactivation as a risk factor for Sjögren’s syndrome. J Immunol. 188(9):4654–4662. doi:10.4049/jimmunol.1101575.
   PubMed Web of Science ®Google Scholar
• Ishibashi H, Imakiire S, Goto M, Nomaru R, Shibata M, Matsuoka H, Yasuda H, Yamashima T, Sakisaka H, Tanabe T, et al. 2022. Epstein-Barr virus-positive intestinal diffuse large B-cell lymphoma in a Japanese patient with celiac disease: first reported case and a literature review. Intern Med. 61(3):329–334. doi:10.2169/internalmedicine.7876-21.
   PubMed Web of Science ®Google Scholar
• Ishimaru N, Takagi A, Kohashi M, Yamada A, Arakaki R, Kanno J, Hayashi Y. 2009. Neonatal exposure to low-dose 2,3,7,8-tetrachlorodibenzo-p-dioxin causes autoimmunity due to the disruption of T cell tolerance. J Immunol. 182(10):6576–6586. doi:10.4049/jimmunol.0802289.
   PubMed Web of Science ®Google Scholar
• Izadi S, Najafizadeh SR, Nejati A, Teymoori-Rad M, Shahmahmoodi S, Golsaz Shirazi F, et al. 2021. Overall status of Epstein-Barr virus infection, IFN-a, and TLR-7/9 in patients with systemic lupus erythematous. Iran J Immunol. 18(3):230–240.
   PubMed Web of Science ®Google Scholar
• Izawa K, Martin E, Soudais C, Bruneau J, Boutboul D, Rodriguez R, Lenoir C, Hislop AD, Besson C, Touzot F, et al. 2017. Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. J Exp Med. 214(1):73–89. doi:10.1084/jem.20160784.
   PubMed Web of Science ®Google Scholar
• James JA, Robertson JM. 2012. Lupus and Epstein-Barr. Curr Opin Rheumatol. 24(4):383–388. doi:10.1097/BOR.0b013e3283535801.
   PubMed Web of Science ®Google Scholar
• Jog NR, Chakravarty EF, Guthridge JM, James JA. 2018. Epstein Barr virus interleukin 10 suppresses anti-inflammatory phenotype in human monocytes. Front Immunol. 9:2198. doi:10.3389/fimmu.2018.02198.
   PubMed Web of Science ®Google Scholar
• Jog NR, James JA. 2020. Epstein Barr virus and autoimmune responses in systemic lupus erythematosus. Front Immunol. 11:623944. doi:10.3389/fimmu.2020.623944.
   PubMed Web of Science ®Google Scholar
• Jog NR, McClain MT, Heinlen LD, Gross T, Towner R, Guthridge JM, Axtell RC, Pardo G, Harley JB, James JA. 2020. Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. J Autoimmun. 106:102332. doi:10.1016/j.jaut.2019.102332.
   PubMed Web of Science ®Google Scholar
• Kato S, Shimizu H, Tomii S, Uchida H, Kawamoto A, Hibiya S, Motobayashi M, Takenaka K, Fujii T, Saito E, et al. 2021. Substantial Epstein-Barr virus reactivation in a case of severe refractory ulcerative colitis: a possible role in exacerbation. Clin J Gastroenterol. 14(2):584–588. doi:10.1007/s12328-020-01319-w.
   PubMed Web of Science ®Google Scholar
• Katsuyama T, Sada K-E, Yan M, Zeggar S, Hiramatsu S, Miyawaki Y, Ohashi K, Morishita M, Watanabe H, Katsuyama E, et al. 2017. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents. Mod Rheumatol. 27(5):773–777. doi:10.1080/14397595.2016.1259714.
   PubMed Web of Science ®Google Scholar
• Keane JT, Afrasiabi A, Schibeci SD, Swaminathan S, Parnell GP, Booth DR. 2021. The interaction of Epstein-Barr virus encoded transcription factor EBNA2 with multiple sclerosis risk loci is dependent on the risk genotype. EBioMedicine. 71:103572. doi:10.1016/j.ebiom.2021.103572.
   PubMed Web of Science ®Google Scholar
• Khatri B, Tessneer KL, Rasmussen A, Aghakhanian F, Reksten TR, Adler A, Alevizos I, Anaya J-M, Aqrawi LA, Baecklund E, et al. 2022. Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells. Nat Commun. 13(1):4287. doi:10.1038/s41467-022-30773-y.
   PubMed Web of Science ®Google Scholar
• Kivity S, Arango MT, Ehrenfeld M, Tehori O, Shoenfeld Y, Anaya J-M, Agmon-Levin N. 2014. Infection and autoimmunity in Sjogren’s syndrome: a clinical study and comprehensive review. J Autoimmun. 51:17–22. doi:10.1016/j.jaut.2014.02.008.
   PubMed Web of Science ®Google Scholar
• Klatt T, Ouyang Q, Flad T, Koetter I, Buhring HJ, Kalbacher H. 2005. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis. J Rheumatol. 32(2):239–251.
   PubMed Web of Science ®Google Scholar
• Knippenberg S, Peelen E, Smolders J, Thewissen M, Menheere P, Cohen Tervaert JW, Hupperts R, Damoiseaux J. 2011. Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission. J Neuroimmunol. 239(1-2):80–86. doi:10.1016/j.jneuroim.2011.08.019.
   PubMed Web of Science ®Google Scholar
• Koji H, Yazawa T, Nakabayashi K, Fujioka Y, Kamma H, Yamada A. 2016. CD8-positive T-cell lymphoproliferative disorder associated with Epstein-Barr virus-infected B-cells in a rheumatoid arthritis patient under methotrexate treatment. Mod Rheumatol. 26(2):271–275. doi:10.3109/14397595.2013.850613.
   PubMed Web of Science ®Google Scholar
• Kumata K, Nagata K, Matsushita M, Kuwamoto S, Kato M, Murakami I, Fukata S, Hayashi K. 2016. Thyrotropin receptor antibody (TRAb)-IgM levels are markedly higher than TRAb-IgG levels in Graves’ disease patients and controls, and TRAb-IgM production is related to Epstein-Barr virus reactivation. Viral Immunol. 29(8):459–463. doi:10.1089/vim.2016.0043.
   PubMed Web of Science ®Google Scholar
• Kurita D, Miyoshi H, Ichikawa A, Kato K, Imaizumi Y, Seki R, Sato K, Sasaki Y, Kawamoto K, Shimono J, et al. 2019. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors. Am J Surg Pathol. 43(7):869–884. doi:10.1097/PAS.0000000000001271.
   PubMed Web of Science ®Google Scholar
• Läderach F, Münz C. 2021. Epstein Barr virus exploits genetic susceptibility to increase multiple sclerosis risk. Microorganisms. 9(11):2191. doi:10.3390/microorganisms9112191.
   PubMed Web of Science ®Google Scholar
• Lanz TV, Brewer RC, Ho PP, Moon J-S, Jude KM, Fernandez D, Fernandes RA, Gomez AM, Nadj G-S, Bartley CM, et al. 2022. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 603(7900):321–327. doi:10.1038/s41586-022-04432-7.
   PubMed Web of Science ®Google Scholar
• Lapsia S, Koganti S, Spadaro S, Rajapakse R, Chawla A, Bhaduri-McIntosh S. 2016. Anti-TNFalpha therapy for inflammatory bowel diseases is associated with Epstein-Barr virus lytic activation. J Med Virol. 88(2):312–318. doi:10.1002/jmv.24331.
   PubMed Web of Science ®Google Scholar
• Lenti MV, Rossi CM, Melazzini F, Gastaldi M, Bugatti S, Rotondi M, Bianchi PI, Gentile A, Chiovato L, Montecucco C, et al. 2022. Seronegative autoimmune diseases: a challenging diagnosis. Autoimmun Rev. 21(9):103143. doi:10.1016/j.autrev.2022.103143.
   PubMed Web of Science ®Google Scholar
• Lerner MR, Andrews NC, Miller G, Steitz JA. 1981. Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A. 78(2):805–809. doi:10.1073/pnas.78.2.805.
   PubMed Web of Science ®Google Scholar
• Levet S, Charvet B, Bertin A, Deschaumes A, Perron H, Hober D. 2019. Human endogenous retroviruses and type 1 diabetes. Curr Diab Rep. 19(12):141. doi:10.1007/s11892-019-1256-9.
   PubMed Web of Science ®Google Scholar
• Levin LI, Munger KL, O’Reilly EJ, Falk KI, Ascherio A. 2010. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol. 67(6):824–830. doi:10.1002/ana.21978.
   PubMed Web of Science ®Google Scholar
• Li X, Chen N, You P, Peng T, Chen G, Wang J, Li J, Liu Y. 2019. The status of Epstein-Barr virus infection in intestinal mucosa of Chinese patients with inflammatory bowel disease. Digestion. 99(2):126–132. doi:10.1159/000489996.
   PubMed Web of Science ®Google Scholar
• Lindsey JW, deGannes SL, Pate KA, Zhao X. 2016. Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein L. Mol Immunol. 69:7–12. doi:10.1016/j.molimm.2015.11.007.
   PubMed Web of Science ®Google Scholar
• Lindsey JW. 2017. Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins. J Neuroimmunol. 310:131–134. doi:10.1016/j.jneuroim.2017.07.013.
   PubMed Web of Science ®Google Scholar
• Liu X, Alli R, Steeves M, Nguyen P, Vogel P, Geiger TL. 2012. The T cell response to IL-10 alters cellular dynamics and paradoxically promotes central nervous system autoimmunity. J Immunol. 189(2):669–678. doi:10.4049/jimmunol.1200607.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li Y, Li Y, Wu S, Tian X, Tang T, Sun H, He C. 2021. Clinical features of intestinal ulcers complicated by Epstein-Barr virus infection: importance of active infection. Dis Markers. 2021:6627620. doi:10.1155/2021/6627620.
   PubMed Web of Science ®Google Scholar
• Lomakin Y, Arapidi GP, Chernov A, Ziganshin R, Tcyganov E, Lyadova I, Butenko IO, Osetrova M, Ponomarenko N, Telegin G, et al. 2017. Exposure to the Epstein-Barr viral antigen latent membrane protein 1 induces myelin-reactive antibodies in vivo. Front Immunol. 8:777. doi:10.3389/fimmu.2017.00777.
   PubMed Web of Science ®Google Scholar
• Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJJ, Joosten LAB, van den Berg WB. 2004. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50(2):650–659. doi:10.1002/art.20001.
   PubMed Web of Science ®Google Scholar
• Lucas RM, Hughes AM, Lay M-LJ, Ponsonby A-L, Dwyer DE, Taylor BV, Pender MP. 2011. Epstein-Barr virus and multiple sclerosis. J Neurol Neurosurg Psychiatry. 82(10):1142–1148. doi:10.1136/jnnp-2011-300174.
   PubMed Web of Science ®Google Scholar
• Magro F, Santos-Antunes J, Albuquerque A, Vilas-Boas F, Macedo GN, Nazareth N, Lopes S, Sobrinho-Simões J, Teixeira S, Dias CC, et al. 2013. Epstein-Barr virus in inflammatory bowel disease-correlation with different therapeutic regimens. Inflamm Bowel Dis. 19(8):1710–1716. doi:10.1097/MIB.0b013e318281f31c.
   PubMed Web of Science ®Google Scholar
• Mameli G, Poddighe L, Mei A, Uleri E, Sotgiu S, Serra C, Manetti R, Dolei A. 2012. Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: inference for multiple sclerosis. PLoS One. 7(9):e44991. doi:10.1371/journal.pone.0044991.
   PubMed Web of Science ®Google Scholar
• Márquez AC, Horwitz MS. 2015. The role of latently infected B cells in CNS autoimmunity. Front Immunol. 6:544. doi:10.3389/fimmu.2015.00544.
   PubMed Web of Science ®Google Scholar
• Masuoka S, Kusunoki N, Takamatsu R, Takahashi H, Tsuchiya K, Kawai S, Nanki T. 2018. Epstein-Barr virus infection and variants of Epstein-Barr nuclear antigen-1 in synovial tissues of rheumatoid arthritis. PLoS One. 13(12):e0208957. doi:10.1371/journal.pone.0208957.
   PubMed Web of Science ®Google Scholar
• McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. 2005. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med. 11(1):85–89. doi:10.1038/nm1167.
   PubMed Web of Science ®Google Scholar
• McDermott M, Molloy M, Buckley J, Greally J. 1989. Antibodies to Epstein-Barr viral antigens in familial rheumatoid arthritis. Ir J Med Sci. 158(8):203–205. doi:10.1007/BF02943612.
   PubMed Web of Science ®Google Scholar
• Middeldorp JM. 2015. Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease. Curr Top Microbiol Immunol. 391:289–323. doi:10.1007/978-3-319-22834-1_10.
   PubMed Web of Science ®Google Scholar
• Miura M, Shimizu H, Saito D, Miyoshi J, Matsuura M, Kudo T, Hirayama D, Yoshida M, Arai K, Iwama I, et al. 2021. Multicenter, cross-sectional, observational study on Epstein-Barr viral infection status and thiopurine use by age group in patients with inflammatory bowel disease in Japan (EBISU study). J Gastroenterol. 56(12):1080–1091. doi:10.1007/s00535-021-01832-w.
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, et al. 2012. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 142(1):46–54.e42; quiz e30. doi:10.1053/j.gastro.2011.10.001.
   PubMed Web of Science ®Google Scholar
• Moschen AR, Tilg H, Raine T. 2019. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 16(3):185–196. doi:10.1038/s41575-018-0084-8.
   PubMed Web of Science ®Google Scholar
• Mouat IC, Morse ZJ, Shanina I, Brown KL, Horwitz MS. 2021. Latent gammaherpesvirus exacerbates arthritis through modification of age-associated B cells. Elife. 10:e67024. doi:10.7554/eLife.67024.
   PubMed Web of Science ®Google Scholar
• Munroe ME, Anderson JR, Gross TF, Stunz LL, Bishop GA, James JA. 2020. Epstein-Barr functional mimicry: pathogenicity of oncogenic latent membrane protein-1 in systemic lupus erythematosus and autoimmunity. Front Immunol. 11:606936. doi:10.3389/fimmu.2020.606936.
   PubMed Web of Science ®Google Scholar
• Nagata K, Fukata S, Kanai K, Satoh Y, Segawa T, Kuwamoto S, Sugihara H, Kato M, Murakami I, Hayashi K, et al. 2011. The influence of Epstein-Barr virus reactivation in patients with Graves’ disease. Viral Immunol. 24(2):143–149. doi:10.1089/vim.2010.0072.
   PubMed Web of Science ®Google Scholar
• Nagata K, Hara S, Nakayama Y, Higaki K, Sugihara H, Kuwamoto S, Matsushita M, Kato M, Tanio S, Ishiguro K, et al. 2018. Epstein-Barr virus lytic reactivation induces IgG4 production by host B lymphocytes in Graves’ disease patients and controls: A subset of graves’ disease is an IgG4-related disease-like condition. Viral Immunol. 31(8):540–547. doi:10.1089/vim.2018.0042.
   PubMed Web of Science ®Google Scholar
• Nagata K, Kumata K, Nakayama Y, Satoh Y, Sugihara H, Hara S, Matsushita M, Kuwamoto S, Kato M, Murakami I, et al. 2017. Epstein-Barr virus lytic reactivation activates B cells polyclonally and induces activation-induced cytidine deaminase expression: a mechanism underlying autoimmunity and its contribution to Graves’ disease. Viral Immunol. 30(3):240–249. doi:10.1089/vim.2016.0179.
   PubMed Web of Science ®Google Scholar
• Najafipoor A, Roghanian R, Zarkesh-Esfahani SH, Bouzari M, Etemadifar M. 2015. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients. Cell Immunol. 294(1):9–12. doi:10.1016/j.cellimm.2015.01.009.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Burastero SE, Ueki Y, Larrick JW, Notkins AL, Casali P. 1988. Probing the normal and autoimmune B cell repertoire with Epstein-Barr virus. Frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto’s disease and systemic lupus erythematosus. J Immunol. 141(12):4165–4172. doi:10.4049/jimmunol.141.12.4165.
   PubMed Web of Science ®Google Scholar
• Navone R, Lunardi C, Gerli R, Tinazzi E, Peterlana D, Bason C, Corrocher R, Puccetti A. 2005. Identification of tear lipocalin as a novel autoantigen target in Sjögren’s syndrome. J Autoimmun. 25(3):229–234. doi:10.1016/j.jaut.2005.09.021.
   PubMed Web of Science ®Google Scholar
• Nielsen TR, Rostgaard K, Askling J, Steffensen R, Oturai A, Jersild C, Koch-Henriksen N, Sørensen PS, Hjalgrim H. 2009. Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Mult Scler. 15(4):431–436. doi:10.1177/1352458508100037.
   PubMed Web of Science ®Google Scholar
• Niiro H, Otsuka T, Abe M, Satoh H, Ogo T, Nakano T, Furukawa Y, Niho Y. 1992. Epstein-Barr virus BCRF1 gene product (viral interleukin 10) inhibits superoxide anion production by human monocytes. Lymphokine Cytokine Res. 11(5):209–214.
   PubMedGoogle Scholar
• Noviello D, Mager R, Roda G, Borroni RG, Fiorino G, Vetrano S. 2021. The IL23-IL17 immune axis in the treatment of ulcerative colitis: successes, defeats, and ongoing challenges. Front Immunol. 12:611256. doi:10.3389/fimmu.2021.611256.
   PubMed Web of Science ®Google Scholar
• Olsson T, Barcellos LF, Alfredsson L. 2017. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 13(1):25–36. doi:10.1038/nrneurol.2016.187.
   PubMed Web of Science ®Google Scholar
• Otsuka K, Sato M, Tsunematsu T, Ishimaru N. 2022. Virus Infections Play Crucial Roles in the Pathogenesis of Sjögren’s Syndrome. Viruses. 14(7):1474. doi:10.3390/v14071474.
   PubMed Web of Science ®Google Scholar
• Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH. 2003. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol. 171(5):2725–2733. doi:10.4049/jimmunol.171.5.2725.
   PubMed Web of Science ®Google Scholar
• Pakpoor J, Disanto G, Gerber JE, Dobson R, Meier UC, Giovannoni G, Ramagopalan SV. 2013. The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler. 19(2):162–166. doi:10.1177/1352458512449682.
   PubMed Web of Science ®Google Scholar
• Parkkonen P, Hyoty H, Ilonen J, Reijonen H, Yla-Herttuala S, Leinikki P. 1994. Antibody reactivity to an Epstein-Barr virus BERF4-encoded epitope occurring also in Asp-57 region of HLA-DQ8 beta chain. Childhood Diabetes in Finland Study Group. Clin Exp Immunol. 95(2):287–293.
   PubMed Web of Science ®Google Scholar
• Pender MP. 2012. CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis. Autoimmune Dis. 2012:189096. doi:10.1155/2012/189096.
   PubMedGoogle Scholar
• Perfetti V, Baldanti F, Lenti MV, Vanoli A, Biagi F, Gatti M, Riboni R, Dallera E, Paulli M, Pedrazzoli P, et al. 2016. Detection of active Epstein-Barr virus infection in duodenal mucosa of patients with refractory celiac disease. Clin Gastroenterol Hepatol. 14(8):1216–1220. doi:10.1016/j.cgh.2016.03.022.
   PubMed Web of Science ®Google Scholar
• Pezhouh MK, Miller JA, Sharma R, Borzik D, Eze O, Waters K, Westerhoff MA, Parian AM, Lazarev MG, Voltaggio L, et al. 2018. Refractory inflammatory bowel disease: is there a role for Epstein-Barr virus? A case-controlled study using highly sensitive Epstein-Barr virus-encoded small RNA1 in situ hybridization. Hum Pathol. 82:187–192. doi:10.1016/j.humpath.2018.08.001.
   PubMed Web of Science ®Google Scholar
• Pisetsky DS. 2023. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 19(8):509–524. doi:10.1038/s41581-023-00720-1.
   PubMed Web of Science ®Google Scholar
• Pohl D, Krone B, Rostasy K, Kahler E, Brunner E, Lehnert M, Wagner H-J, Gärtner J, Hanefeld F. 2006. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology. 67(11):2063–2065. doi:10.1212/01.wnl.0000247665.94088.8d.
   PubMed Web of Science ®Google Scholar
• Pyzik A, Grywalska E, Matyjaszek-Matuszek B, Ludian J, Kiszczak-Bochynska E, Smolen A, et al. 2019. Does the Epstein-Barr virus play a role in the pathogenesis of Graves’ disease? Int J Mol Sci. 20(13):3145.
   PubMed Web of Science ®Google Scholar
• Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, Zhong R. 2015. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 74(11):1983–1989. doi:10.1136/annrheumdis-2014-205375.
   PubMed Web of Science ®Google Scholar
• Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, Antel J. 1998. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest. 102(5):1045–1050. doi:10.1172/JCI3568.
   PubMed Web of Science ®Google Scholar
• Quaglia M, Merlotti G, De Andrea M, Borgogna C, Cantaluppi V. 2021. Viral infections and systemic lupus erythematosus: new players in an old story. Viruses. 13(2):277. doi:10.3390/v13020277.
   PubMed Web of Science ®Google Scholar
• Radu AF, Bungau SG. 2021. Management of rheumatoid arthritis: an overview. Cells. 10(11):2857. doi:10.3390/cells10112857.
   PubMed Web of Science ®Google Scholar
• Ram R, Mehta M, Nguyen QT, Larma I, Boehm BO, Pociot F, Concannon P, Morahan G. 2016. Systematic evaluation of genes and genetic variants associated with type 1 diabetes susceptibility. J Immunol. 196(7):3043–3053. doi:10.4049/jimmunol.1502056.
   PubMedGoogle Scholar
• Ramasamy R, Mohammed F, Meier UC. 2020. HLA DR2b-binding peptides from human endogenous retrovirus envelope, Epstein-Barr virus and brain proteins in the context of molecular mimicry in multiple sclerosis. Immunol Lett. 217:15–24. doi:10.1016/j.imlet.2019.10.017.
   PubMed Web of Science ®Google Scholar
• Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A. 2015. Latent membrane protein LMP2A impairs recognition of EBV-infected cells by CD8+ T cells. PLoS Pathog. 11(6):e1004906. doi:10.1371/journal.ppat.1004906.
   PubMed Web of Science ®Google Scholar
• Rasmussen NS, Draborg AH, Nielsen CT, Jacobsen S, Houen G. 2015. Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients. Scand J Rheumatol. 44(2):143–149. doi:10.3109/03009742.2014.973061.
   PubMed Web of Science ®Google Scholar
• Richardson SJ, Horwitz MS. 2014. Is type 1 diabetes "going viral"? Diabetes. 63(7):2203–2205. doi:10.2337/db14-0510.
   PubMed Web of Science ®Google Scholar
• Rizzo AG, Orlando A, Gallo E, Bisanti A, Sferrazza S, Montalbano LM, Macaluso FS, Cottone M. 2017. Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis? J Clin Virol. 97:1–3. doi:10.1016/j.jcv.2017.10.009.
   PubMed Web of Science ®Google Scholar
• Rolf L, Muris A-H, Mathias A, Du Pasquier R, Koneczny I, Disanto G, Kuhle J, Ramagopalan S, Damoiseaux J, Smolders J, et al. 2018. Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. Mult Scler. 24(10):1280–1287. doi:10.1177/1352458517722646.
   PubMed Web of Science ®Google Scholar
• Rose NR. 2016. Prediction and prevention of autoimmune disease in the 21st century: a review and preview. Am J Epidemiol. 183(5):403–406. doi:10.1093/aje/kwv292.
   PubMed Web of Science ®Google Scholar
• Ruiz-Pablos M. 2022. CD4+ Cytotoxic T cells involved in the development of EBV-associated diseases. Pathogens. 11(8):831. doi:10.3390/pathogens11080831.
   PubMed Web of Science ®Google Scholar
• Ryan JL, Shen Y-J, Morgan DR, Thorne LB, Kenney SC, Dominguez RL, Gulley ML. 2012. Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. Dig Dis Sci. 57(7):1887–1898. doi:10.1007/s10620-012-2116-5.
   PubMed Web of Science ®Google Scholar
• Salek-Ardakani S, Arrand JR, Mackett M. 2002. Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: implications for immune evasion by EBV. Virology. 304(2):342–351. doi:10.1006/viro.2002.1716.
   PubMed Web of Science ®Google Scholar
• Sankaran-Walters S, Ransibrahmanakul K, Grishina I, Hung J, Martinez E, Prindiville T, Dandekar S. 2011. Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. J Clin Virol. 50(1):31–36. doi:10.1016/j.jcv.2010.09.011.
   PubMed Web of Science ®Google Scholar
• Sanosyan A, Daien C, Nutz A, Bollore K, Bedin A-S, Morel J, Zimmermann V, Nocturne G, Peries M, Guigue N, et al. 2019. Discrepancy of serological and molecular patterns of circulating Epstein-Barr virus reactivation in primary Sjögren’s syndrome. Front Immunol. 10:1153. doi:10.3389/fimmu.2019.01153.
   PubMed Web of Science ®Google Scholar
• Schmitt H, Neurath MF, Atreya R. 2021. Role of the IL23/IL17 Pathway in Crohn’s Disease. Front Immunol. 12:622934. doi:10.3389/fimmu.2021.622934.
   PubMed Web of Science ®Google Scholar
• Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, et al. 2007. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 204(12):2899–2912. doi:10.1084/jem.20071030.
   PubMed Web of Science ®Google Scholar
• Shaffer DR, Savoldo B, Yi Z, Chow KKH, Kakarla S, Spencer DM, Dotti G, Wu M-F, Liu H, Kenney S, et al. 2011. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood. 117(16):4304–4314. doi:10.1182/blood-2010-04-278218.
   PubMed Web of Science ®Google Scholar
• Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. 2019. Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. Viruses. 11(8):762. doi:10.3390/v11080762.
   PubMed Web of Science ®Google Scholar
• Smith DA, Germolec DR. 1999. Introduction to immunology and autoimmunity. Environ Health Perspect. 107 Suppl 5(Suppl 5):661–665. doi:10.1289/ehp.99107s5661.
   PubMedGoogle Scholar
• Stewart JP, Rooney CM. 1992. The interleukin-10 homolog encoded by Epstein-Barr virus enhances the reactivation of virus-specific cytotoxic T cell and HLA-unrestricted killer cell responses. Virology. 191(2):773–782. doi:10.1016/0042-6822(92)90253-l.
   PubMed Web of Science ®Google Scholar
• Su R, Li Z, Wang Y, Liu Y, Zheng X, Gao C, et al. 2020. Imbalance between Th17 and regulatory T cells in patients with systemic lupus erythematosus combined EBV/CMV viraemia. Clin Exp Rheumatol. 38(5):864–873.
   PubMed Web of Science ®Google Scholar
• Szabo K, Papp G, Barath S, Gyimesi E, Szanto A, Zeher M. 2013. Follicular helper T cells may play an important role in the severity of primary Sjögren’s syndrome. Clin Immunol. 147(2):95–104. doi:10.1016/j.clim.2013.02.024.
   PubMed Web of Science ®Google Scholar
• Takeda T, Mizugaki Y, Matsubara L, Imai S, Koike T, Takada K. 2000. Lytic Epstein-Barr virus infection in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum. 43(6):1218–1225. doi:10.1002/1529-0131(200006)43:6<1218::AID-ANR4>3.0.CO;2-2.
   PubMedGoogle Scholar
• Takei M, Kitamura N, Nagasawa Y, Tsuzuki H, Iwata M, Nagatsuka Y, Nakamura H, Imai K, Fujiwara S. 2022. Are viral infections key inducers of autoimmune diseases? Focus on Epstein-Barr virus. Viruses. 14(9):1900. doi:10.3390/v14091900.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Sato Y, Yasui H, Ozawa H, Ohno K, Takata K, Gion Y, Orita Y, Tachibana T, Itoh T, et al. 2014. Epstein-Barr virus-infected cells in IgG4-related lymphadenopathy with comparison with extranodal IgG4-related disease. Am J Surg Pathol. 38(7):946–955. doi:10.1097/PAS.0000000000000206.
   PubMed Web of Science ®Google Scholar
• Tamoto N, Nagata K, Hara S, Nakayama Y, Kuwamoto S, Matsushita M, Kato M, Hayashi K. 2019. Subclinical Epstein-Barr virus primary infection and lytic reactivation induce thyrotropin receptor autoantibodies. Viral Immunol. 32(9):362–369. doi:10.1089/vim.2019.0086.
   PubMed Web of Science ®Google Scholar
• Taussig D, Wine Y. 2021. When a virus lies in wait. Elife. 10:e71121. doi:10.7554/eLife.71121.
   PubMed Web of Science ®Google Scholar
• Tengvall K, Huang J, Hellström C, Kammer P, Biström M, Ayoglu B, Lima Bomfim I, Stridh P, Butt J, Brenner N, et al. 2019. Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc Natl Acad Sci U S A. 116(34):16955–16960. doi:10.1073/pnas.1902623116.
   PubMed Web of Science ®Google Scholar
• Tian J, Zhang D, Yao X, Huang Y, Lu Q. 2023. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 82(3):351–356. doi:10.1136/ard-2022-223035.
   PubMed Web of Science ®Google Scholar
• Trier N, Izarzugaza J, Chailyan A, Marcatili P, Houen G. 2018. Human MHC-II with shared epitope motifs are optimal Epstein-Barr virus glycoprotein 42 ligands-relation to rheumatoid arthritis. Int J Mol Sci. 19(1):317. doi:10.3390/ijms19010317.
   PubMed Web of Science ®Google Scholar
• Trier NH, Holm BE, Heiden J, Slot O, Locht H, Lindegaard H, Svendsen A, Nielsen CT, Jacobsen S, Theander E, et al. 2018. Antibodies to a strain-specific citrullinated Epstein-Barr virus peptide diagnoses rheumatoid arthritis. Sci Rep. 8(1):3684. doi:10.1038/s41598-018-22058-6.
   PubMedGoogle Scholar
• Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, Sefia E, Meager A, Elia A, Middeldorp JM, Clemens M, et al. 2012. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology. 78(1):15–23. doi:10.1212/WNL.0b013e31823ed057.
   PubMed Web of Science ®Google Scholar
• van Noort JM, Bajramovic JJ, Plomp AC, van Stipdonk MJ. 2000. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol. 105(1):46–57. doi:10.1016/s0165-5728(00)00181-8.
   PubMed Web of Science ®Google Scholar
• van Sechel AC, Bajramovic JJ, van Stipdonk MJ, Persoon-Deen C, Geutskens SB, van Noort JM. 1999. EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. Journal of Immunology. 162(1):129–135. doi:10.4049/jimmunol.162.1.129.
   PubMed Web of Science ®Google Scholar
• Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, et al. 2020. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 26(14):1816–1821. doi:10.1177/1352458520970841.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang FS, Gershwin ME. 2015. Human autoimmune diseases: a comprehensive update. J Intern Med. 278(4):369–395. doi:10.1111/joim.12395.
   PubMed Web of Science ®Google Scholar
• Wang SC, Liao JY. 2022. Epidemiologic implication of the association between herpes simplex virus infection and the risk of type 1 diabetes mellitus: a nationwide case-control study in Taiwan. Int J Environ Res Public Health. 19(13):7832. doi:10.3390/ijerph19137832.
   Web of Science ®Google Scholar
• Williams H, McAulay K, Macsween KF, Gallacher NJ, Higgins CD, Harrison N, Swerdlow AJ, Crawford DH. 2005. The immune response to primary EBV infection: a role for natural killer cells. Br J Haematol. 129(2):266–274. doi:10.1111/j.1365-2141.2005.05452.x.
   PubMed Web of Science ®Google Scholar
• Willson TA, Kuhn BR, Jurickova I, Gerad S, Moon D, Bonkowski E, Carey R, Collins MH, Xu H, Jegga AG, et al. 2012. STAT3 genotypic variation and cellular STAT3 activation and colon leukocyte recruitment in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 55(1):32–43. doi:10.1097/MPG.0b013e318246be78.
   PubMed Web of Science ®Google Scholar
• Wilson MR, Arroyave CM, Miles L, Tan EM. 1977. Immune reactants in cryoproteins. Relationship to complement activation. Ann Rheum Dis. 36(6):540–548. doi:10.1136/ard.36.6.540.
   PubMed Web of Science ®Google Scholar
• Wood RA, Guthridge L, Thurmond E, Guthridge CJ, Kheir JM, Bourn RL, Wagner CA, Chen H, DeJager W, Macwana SR, et al. 2021. Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus. J Transl Autoimmun. 4:100117. doi:10.1016/j.jtauto.2021.100117.
   PubMedGoogle Scholar
• Woulfe J, Gray MT, Ganesh MS, Middeldorp JM. 2016. Human serum antibodies against EBV latent membrane protein 1 cross-react with α-synuclein. Neurol Neuroimmunol Neuroinflamm. 3(4):e239. doi:10.1212/NXI.0000000000000239.
   PubMed Web of Science ®Google Scholar
• Wu S, He C, Tang TY, Li YQ. 2019. A review on co-existent Epstein-Barr virus-induced complications in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 31(9):1085–1091. doi:10.1097/MEG.0000000000001474.
   PubMed Web of Science ®Google Scholar
• Wucherpfennig KW, Strominger JL. 1995. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell. 80(5):695–705. doi:10.1016/0092-8674(95)90348-8.
   PubMed Web of Science ®Google Scholar
• Xu W, Jiang X, Chen J, Mao Q, Zhao X, Sun X, Zhong L, Rong L. 2020. Chronic active Epstein-Barr virus infection involving gastrointestinal tract mimicking inflammatory bowel disease. BMC Gastroenterol. 20(1):257. doi:10.1186/s12876-020-01395-9.
   PubMed Web of Science ®Google Scholar
• Xuan J, Ji Z, Wang B, Zeng X, Chen R, He Y, Rao P, Wu P, Shi G. 2020. Serological Evidence for the Association Between Epstein-Barr Virus Infection and Sjögren’s Syndrome. Front Immunol. 11:590444. doi:10.3389/fimmu.2020.590444.
   PubMed Web of Science ®Google Scholar
• Yamashita K, Sato R, Fukumoto R, Ofuji Y, Nagamoto T, Kubono H, Kawamura M, Suzuki K. 2022. Epstein-Barr viral corneal stromal keratitis occurring during rheumatoid arthritis treatment: a case report. BMC Ophthalmol. 22(1):31. doi:10.1186/s12886-022-02257-6.
   PubMed Web of Science ®Google Scholar
• Yang J, Sundrud MS, Skepner J, Yamagata T. 2014. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci. 35(10):493–500. doi:10.1016/j.tips.2014.07.006.
   PubMed Web of Science ®Google Scholar
• Yin H, Zhao M, Wu X, Gao F, Luo Y, Ma L, Liu S, Zhang G, Chen J, Li F, et al. 2010. Hypomethylation and overexpression of CD70 (TNFSF7) in CD4+ T cells of patients with primary Sjögren’s syndrome. J Dermatol Sci. 59(3):198–203. doi:10.1016/j.jdermsci.2010.06.011.
   PubMed Web of Science ®Google Scholar
• Yogev N, Bedke T, Kobayashi Y, Brockmann L, Lukas D, Regen T, Croxford AL, Nikolav A, Hövelmeyer N, von Stebut E, et al. 2022. CD4(+) T-cell-derived IL-10 promotes CNS inflammation in mice by sustaining effector T cell survival. Cell Rep. 38(13):110565. doi:10.1016/j.celrep.2022.110565.
   PubMed Web of Science ®Google Scholar
• Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita T, Horikawa M, Kountikov EI, Spolski R, Poe JC, Leonard WJ, Tedder TF, et al. 2012. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature. 491(7423):264–268. doi:10.1038/nature11501.
   PubMed Web of Science ®Google Scholar
• Yu H, Nagafuchi Y, Fujio K. 2021. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 11(7):928. doi:10.3390/biom11070928.
   PubMed Web of Science ®Google Scholar
• Zandman-Goddard G, Shoenfeld Y. 2005. Infections and SLE. Autoimmunity. 38(7):473–485. doi:10.1080/08916930500285352.
   PubMed Web of Science ®Google Scholar
• Zhou H, Schmidt SCS, Jiang S, Willox B, Bernhardt K, Liang J, Johannsen EC, Kharchenko P, Gewurz BE, Kieff E, et al. 2015. Epstein-Barr virus oncoprotein super-enhancers control B cell growth. Cell Host Microbe. 17(2):205–216. doi:10.1016/j.chom.2014.12.013.
   PubMed Web of Science ®Google Scholar
• Zhou J-Q, Zeng L, Zhang Q, Wu X-Y, Zhang M-L, Jing X-T, Wang Y-F, Gan H-T. 2020. Clinical features of Epstein-Barr virus in the intestinal mucosa and blood of patients with inflammatory bowel disease. Saudi J Gastroenterol. 26(6):312–320. doi:10.4103/sjg.SJG_30_20.
   PubMed Web of Science ®Google Scholar
• Ziętara N, Łyszkiewicz M, Krueger A, Weiss S. 2014. B-cell modulation of dendritic-cell function: signals from the far side. Eur J Immunol. 44(1):23–32. doi:10.1002/eji.201344007.
   PubMed Web of Science ®Google Scholar